RxDoctor Payments Data

Brandy Lasley, APRN

Family · Williamsburg, KYNPI 1114267135

Payments from drug & device makers

$677in general payments, 2019–2025

Across 27 payments — averaging $25.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$139
  • AbbVie$125
  • AstraZeneca$84
  • Amgen$71
  • Novartis$59
  • Lilly USA, LLC$48
  • plus $150 from 7 others

What the payments were for

  • Food & beverage$677100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$677 in reported general payments places this provider in the 55th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$2,757
Medicare patients
75
Services billed
131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide61$69,842
EliquisApixaban68$57,262
OzempicSemaglutide51$48,428
JardianceEmpagliflozin38$37,680
JanuviaSitagliptin Phosphate18$23,364
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$15,181
Combivent RespimatIpratropium/Albuterol Sulfate15$7,288
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,828
Albuterol Sulfate HfaAlbuterol Sulfate97$2,229
Atorvastatin Calcium269$1,624
Ventolin HfaAlbuterol Sulfate20$1,238
Pantoprazole Sodium144$1,229
Omeprazole110$1,197
Levothyroxine Sodium173$1,184
Metoprolol Succinate113$1,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$48$69,84261 claims
PfizerEliquis$21$57,26268 claims
Novo NordiskOzempic$16$48,42851 claims
Boehringer IngelheimJardiance, Combivent Respimat$25$44,96753 claims
AstraZenecaBreztri Aerosphere$84$15,18120 claims
AbbVieSynthroid$125$63026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,374 family providers in Kentucky.

Other family in Williamsburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →